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Background: The oxidative stress mechanism is of particular interest in the pathogenesis of glioma, given the high
rate of oxygen metabolism in the brain. Potential links between polymorphisms of antioxidant genes and glioma
risk are currently unknown. We therefore investigated the association between polymorphisms in antioxidant genes
and glioma risk.
Methods: We examined 16 single nucleotide polymorphisms (SNPs) of 9 antioxidant genes (GPX1, CAT, PON1,
NQO1, SOD2/MnSOD, SOD3, and NOS1*2*3) in 384 glioma and 384 control cases in a Chinese hospital-based
case–control study. Genotypes were determined using the OpenArray platform, which employs the chip-based
Taq-Man genotyping technology. The adjusted odds ratio (OR) and 95% confidence interval (CI) were estimated
using unconditional logistic regression.
Results: Using single-locus analysis, we identified four SNPs (SOD2 V16A, SOD3 T58A, GPX1 -46 C/T, and NOS1
3’-UTR) that were significantly associated with the risk of glioma development. To assess the cumulative effects, we
performed a combined unfavourable genotype analysis. Compared with the reference group that exhibited no
unfavourable genotypes, the medium- and high-risk groups exhibited a 1.86-fold (95% CI, 1.30-2.67) and a 4.86-fold
(95% CI, 1.33-17.71) increased risk of glioma, respectively (P-value for the trend < 0.001).
Conclusions: These data suggest that genetic variations in oxidative stress genes might contribute to the aetiology
of glioma.
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Glioma is the most common form of primary brain
tumour in adults and generally exhibits a poor progno-
sis [1-3]. According to the Chinese Health Statistics
Yearbook, the incidence of glioma is approximately
five to ten per 100,000 person-years in China. The inci-
dence rate has steadily increased despite significant
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The aetiology of this malignancy remains largely
unknown. People with inherited diseases such as
Li-Fraumeni disease, Neurofibromatosis type 1, and
Turcot’s disease type 1 exhibit a significantly increased
risk of glioma, and consistent with this diversity of
predisposing genetic backgrounds, large-scale sequen-
cing of the glioblastoma genome has revealed many
genetic alterations [5,6]. Furthermore, there have been
many relevant studies focused on the role of poly-
morphism analysis of candidate genes in glioma risk
[7-10]. Taken together, the evidence thus far provides
us with important insight for our understanding of the
aetiology of and susceptibility for gliomas.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of particular interest in gliomas, given the high rate of
oxygen metabolism in the brain [11]. An excess of oxida-
tive stress, which is triggered by reactive oxygen species
(ROS) or reactive nitrogen species (RNS), appears to in-
crease the predisposition for glioma, as an elevated con-
centration of ROS/RNS can cause DNA damage, repress
the activity of cellular enzymes, influence apoptosis and
proliferation, and promote tumourigenesis [12,13].
To prevent and mitigate damage caused by ROS/RNS
and to maintain redox homeostasis, aerobic organisms
have developed efficient defence systems mediated by
enzymatic and non-enzymatic antioxidants that can act
in a coordinated network [14]. Enzymatic antioxidant
defences include superoxide dismutase (SOD), glutathi-
one peroxidase (GPx), catalase (CAT), paraoxonase
(PON), NADPH-quinone reductase (NQO), and nitric
oxide synthase (NOS). Intrinsic antioxidant enzymes are
vital to the regulation of oxidative stress responses
within cells. Genetic variation in these genes might im-
pact the elimination of ROS/RNS and hence increase
cancer risk through ROS/RNS effects [15].
In humans, single nucleotide polymorphisms (SNPs) ac-
count for a significant proportion of observed genetic muta-
tions and might be associated with cancer risk by altering
the expression levels and functions of the affected genes.
Numerous studies [9,16-24] have investigated the associ-
ation between SNPs in enzymatic antioxidant genes and
cancer risk in cancers, including breast cancer, prostate can-
cer, and a small number of gliomas. To examine whether
genetic variation in antioxidant genes is linked with glioma
susceptibility, we analysed a set of SNPs and assessed their
association with the risk of glioma.
Materials and methods
Study design and population
The study population consisted of a consecutive series
of glioma patients admitted at two centres, specifically,
the Department of Neurosurgery of Jiangsu Province
Hospital (the First Affiliated Hospital of Nanjing Medical
University) and the Chinese Glioma Genome Atlas
(Beijing Tiantan Hospital Neurosurgery Centre), from
2005 to 2010. The inclusion criteria for these cases
necessitated a newly diagnosed (pathologically or histo-
logically) intracranial glioma (International Classifica-
tion of Diseases for Oncology, 9th Edition, codes
9380–9481). Histological diagnosis and grading of the
tumours were performed in compliance with WHO
criteria (World Health Organization, 2007). There were
no gender, ethnicity, or cancer stage restrictions on re-
cruitment. After excluding patients with prior cancer
history during the baseline visit, a total of 447 glioma
patients were invited to participate in the study, of
whom 408 (91%) patients consented. Healthy controlsubjects without a history of cancer were recruited
from the health examination clinics of the same two
hospitals during the same time period.
The controls matched the case distribution for fre-
quencies of age, sex, ethnicity, and smoking status. Four
hundred controls were successfully enrolled. Each par-
ticipant or proxy was asked to read and sign informed
consent agreements in accordance with the require-
ments of the institutional review board of each partici-
pating institution. Following initial patient drop out, 384
glioma patients and 384 cancer-free control patients
were included in the final analysis. The study was
approved by the Ethics Review Board of Nanjing Medical
University.
Data collection
For both the cases and the controls, information on
demographic characteristics, education, occupation,
marital status, personal history, family history of cancer
in first- and second-degree relatives, and lifestyle habits,
including smoking and alcohol consumption, was col-
lected by trained interviewers using a structured ques-
tionnaire. Venous blood was collected at each study
centre from participants and frozen at −70°C for further
molecular analysis.
Selection of genes and polymorphisms
Through an extensive mining of the databases of the
International HapMap Project (HapMap Data Rel 24/
phaseII Nov08) and dbSNP, we identified 16 potential
functional polymorphisms, which were located within
the 50-UTR, 30-UTR, promoter, coding sequence, and
splice sites of nine crucial genes involved in oxidative
stress response. All of these SNPs exhibit a reported
minor allele frequency (MAF) > 0.05 in the general Han
Chinese population (Table 1).
Genotyping
Genomic DNA was isolated from peripheral blood leu-
kocytes using phenol-chloroform extraction and protein-
ase K digestion. Genotyping was performed using the
OpenArray platform (Applied Biosystems, Foster City,
CA, USA), which employs a chip-based Taq-Man geno-
typing technology. Genotype calls were made by Open-
Array SNP Genotyping Analysis Software version 1.0.3.;
laboratory personnel were blinded to the case–control
status of each patient sample. For quality control, ten
per cent of randomly selected samples were reanalysed
with 100% concordant results, and the genotyping suc-
cess rate for the sixteen SNPs ranged from 97.2% to
99.1%. To further confirm the genotyping results,
selected PCR-amplified DNA samples (n = 2, for each
genotype) were genotyped a second time using a direct
sequencing method, and the results were also consistent.
Table 1 Primary information for 16 genotyped SNPs in oxidative pathway genes
Genotyped SNPs Location/or Amino acid change MAF for Chinese in databasea P value for HWE testb % Genotyping rate
GPX1: rs1800668 C>T Promoter 0.078 0.706 99.1
CAT: rs769214 G>A 5’region 0.293 0.275 97.9
CAT: rs7943316 A>T 5’region 0.256 0.822 98.0
PON1: rs854552 T>C 3' UTR 0.179 0.195 99.1
PON1: rs662 G>A nsSNP/Q192R 0.430 0.424 97.7
NQO1: rs10517 C>T 3' UTR 0.381 0.397 97.7
NQO1: rs1800566 T>C nsSNP/S1P 0.478 0.757 97.5
MnSOD: rs4880 T>C nsSNP/V16A 0.146 0.914 98.8
MnSOD: rs5746136 G>A 3' UTR 0.422 0.264 98.7
SOD3: rs2536512 G>A nsSNP/T58A 0.100 0.730 98.6
SOD3: rs2695232 C>T 3' UTR 0.367 0.284 98.6
NOS1: rs2682826 C>T 3' UTR 0.256 0.163 98.0
NOS1: rs1047735 T>C nsSNP/Q902H 0.488 0.522 98.4
NOS2: rs2297518 G>A nsSNP/L608S 0.175 0.426 97.2
NOS2: rs10459953 G>C Promoter 0.489 0.790 99.1
NOS3: rs1799983 G>T nsSNP/D298E 0.111 0.586 97.9
Abbreviations: MAF minor allele frequency, HWE Hardy-Weinberg equilibrium.
aMinor allele frequency in the Chinese (CHB, Han Chinese in Beijing, China) population, as reported in dbSNP database.
bP values were calculated from our control genotype.
Table 2 Distribution of selected host characteristics by
case–control status in Chinese
Variables Case (n = 384) Control (n = 384) P*
Age, y (mean ± SD) 62.4 ± 10.8 61.5 ± 12.1 0.277
Gender, no. (%)
Male 222 (57.8) 217 (56.5) 0.715
Female 162 (42.2) 167 (43.5)
Smoking status, no. (%)
Never 228 (59.4) 218 (56.8) 0.738
Former 70 (18.2) 72 (18.7)
Current 86 (22.4) 94 (24.5)
Pack-years (mean ± SD) 32.7 ± 25.1 30.3 ± 27.7 0.209
Tumor grade, no. (%)
I 41 (10.7) 0
II 176 (45.8) 0
III 86 (22.4) 0
IV 81 (21.1) 0
*P values were derived from the χ2 test for categorical variables (gender and
smoking status) and t test for continuous variables (age and pack-years).
Zhao et al. BMC Cancer 2012, 12:617 Page 3 of 10
http://www.biomedcentral.com/1471-2407/12/617Statistical analysis
All statistical analyses were performed with STATA ver-
sion 10.0 (Stata Corporation, College Station, TX, USA).
The Pearson Chi-squared test was used to assess differ-
ences between the cases and the controls with regard to
categorical variables, such as gender and smoking status,
and to compare observed SNP genotype frequencies
with those expected under Hardy-Weinberg equilibrium
conditions. Student’s t-test was used to test for continu-
ous variables, including age and pack-years. Using un-
conditional logistic regression, we derived odds ratios
(ORs) and confidence intervals (CIs) for each poly-
morphism and associated P-value. Adjusted P-values fac-
tored for variables such as age, gender, smoking status,
and pack-years were calculated as confounders to ex-
clude potential bias. A test of linear trend with the score
was conducted for each SNP using three-level ordinal
variable analysis. To correct for multiple comparison
testing, we applied the false discovery rate (FDR) [25]
method to the P-values to reduce the potential for in-
accurate findings. In addition to single SNP analysis, we
also analysed the association between the total number
of unfavourable genotypes and glioma risk. The un-
favourable genotypes were combined and categorised
according to the tertiles (low, medium, and high risk) of
the number of unfavourable genotypes observed in the
controls. Using the low-risk group as a reference, we cal-
culated the ORs and 95% CIs for the other subgroups
using multivariate logistic regression adjusted for age,




The distribution of data on age, gender and smoking sta-
tus for the cases and controls is shown in Table 2. The
cases and controls were similar in age, gender, and
smoking status. We included a total of 384 cases and
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16 genotyped SNPs in oxidative pathway genes, includ-
ing the location, minor allelic frequencies (MAF), and
Hardy-Weinberg equilibrium (HWE) tests for the 16
SNPs and their genotyping rates. The genotype distribu-
tions in the cases and controls of all SNPs were consist-
ent with Hardy-Weinberg equilibrium.
Main analyses of effects due to individual polymorphisms
As shown in Table 3, four SNPs (SOD2 V16A, SOD3
T58A, GPX1 -46 C/T, and NOS1 3’-UTR) demonstrated
a significant association with glioma risk, as determined
by the dominant model (variant-containing genotypes
versus common homozygote). Compared to SOD2 16Val
homozygotes, carriers with the SOD2 16Ala allele exhib-
ited a more than 1.86-fold increased risk of glioma oc-
currence (adjusted OR = 1.86; 95% CI = 1.35-2.55),
where the risk increased significantly with the increasing
number of variant alleles (P-trend < 0.001). Similarly,
individuals with the SOD3 58A allele exhibited a signifi-
cant association with the risk of glioma occurrence com-
pared to the 58T homozygotes (adjusted OR = 1.64; 95%
CI = 1.20–2.23; P-trend < 0.001). Furthermore, we
observed an increased risk of glioma occurrence asso-
ciated with the GPX1 rs1800668 variant (adjusted OR =
1.18; 95% CI = 0.82–1.69). In contrast, we observed a
decreased glioma risk associated with the NOS1
rs2682826 variant (adjusted OR = 0.61; 95% CI = 0.45-
0.82; P-trend = 0.017).
Combined effects of the unfavourable genotypes
To understand the cumulative effects of these variants
on glioma risk, we performed an unfavourable genotype
analysis for four SNPs that had significant and border-
line significant associations with glioma risk, including
rs1800668 (CC), rs4880 (TT), rs2536512 (GG), and
rs2682826 (TC+ TT). Compared to the reference group
exhibiting no unfavourable genotypes, the OR for the
medium risk group with two unfavourable genotypes
was 1.86 (95% CI, 1.30-2.76), and the OR was increased
to 4.86 (95% CI, 1.33–17.71) for the high-risk group with
3 unfavourable genotypes (Table 4).
Discussion and conclusion
Emerging evidence from in vitro, animal, and human
studies has indicated that ROS/RNS and the activation
of redox-sensitive signalling pathways play a crucial
role in cancer development [26-29]. Such antioxidant
mechanisms are extremely important, as they represent
the direct removal of ROS/RNS, particularly during
gliomatous carcinogenesis. To investigate the potential
association between SNPs in antioxidant defence genes
and the risk of glioma occurrence, we conducted this
case–control study. In this study, we observed astatistically significant association between four SNPs
(SOD2 V16A, SOD3 T58A, GPX1 -46 C/T, and NOS1
3’-UTR) of antioxidant genes and the risk of glioma
occurrence in a Chinese population. Additionally,
three SNPs exhibited statistically significant evidence
of differential dose–response associations. To the best
of our knowledge, this is the first report of an associ-
ation study between antioxidant gene SNPs and glioma
risk in a Chinese population.
SODs are a ubiquitous family and represent the most
important line of antioxidant enzyme defence against
ROS, particularly the superoxide anion radicals [13].
SOD enzymes, which catalyse the spontaneous dismuta-
tion of the superoxide radical into hydrogen peroxide,
are present in all subcellular milieus of the nervous sys-
tem, including the mitochondrial intermembrane space
(SOD1; copper/zinc SOD); the mitochondrial matrix
(SOD2; manganese SOD); and the plasma, lymph, and
synovial fluids (SOD3; extracellular SOD) [30]. Super-
oxide dismutase 2 (SOD2) (also known as manganese
superoxide dismutase [MnSOD]) is an essential defender
against mitochondrial superoxide radicals.
SOD2 converts the superoxide anion radical into
hydrogen peroxide and oxygen within mitochondria and
plays a key role in protecting cells from oxidative dam-
age [31]. In the early stages of carcinogenesis, oxidative
stress and relatively low levels of MnSOD result in DNA
damage and cell injury [32-34]. MnSOD plays a critical
role in the defence against oxidant-induced injury and
apoptosis of rapidly growing cancer cells, and the
tumour-suppressive effects of MnSOD have been well
established [12,14,35]. Whereas Chung-man et al. [36]
and Izutani et al. [37] previously found increased SOD2
levels in cancer cells, other studies have reported ele-
vated MnSOD expression levels in aggressive cancers
compared to benign counterparts, and this increased ex-
pression has been proposed to enhance metastasis fol-
lowing cancer progression, possibly through increased
expression of matrix metalloproteinases (MMP) [38,39],
which is one possible mechanism supporting the role of
SOD2 in cancer invasiveness and metastatic capacity.
The overexpression of SOD2 can also induce increased
levels of hydrogen peroxide (H2O2) [40,41]. H2O2 is a
major intracellular oxidant and induces DNA damage in
glioma cells [42,43]. Although it might be difficult to de-
termine the precise mechanisms that are most relevant
to the pathologies of the patients in this study, the iden-
tification of these two possible mechanisms is consistent
with our results.
To our knowledge, most epidemiological studies have
indicated that SOD2 polymorphisms are linked to clinic-
ally significant increases in colon, gastric, lung, breast,
and prostate cancers [16-20]. These polymorphisms have
also been linked to the development of meningiomas
Table 3 Allelic and genotypic frequencies and risks for glioma in Chinese
Genotyped SNPs MAF Common homozygote (n) Heterozygote (n) Rare homozygote (n) Heterozygote and rare Homozygote (n) P for trend
GPX1 promoter (rs1800668) Case 0.12 301 66 13 79
Control 0.09 314 64 4 68 0.110
OR (95% CI)* Reference 1.05 (0.72-1.53) 3.30 (1.07-10.24) 1.18 (0.82-1.69)
CAT 5’region (rs769214) Case 0.28 198 146 32 178
Control 0.29 192 146 36 182 0.609
OR (95% CI)* Reference 0.93 (0.69- 1.26) 0.83 (0.49- 1.39) 0.91 (0.68- 1.21)
CAT 5’region (rs7943316) Case 0.33 180 140 53 193
Control 0.29 195 153 32 185 0.074
OR (95% CI)* Reference 1.04 (0.77- 1.41) 1.16 (0.75- 1.79) 1.19 (0.89- 1.58)
PON1 3' UTR (rs854552) Case 0.22 237 120 23 143
Control 0.23 231 126 24 150 0.653
OR (95% CI)* Reference 0.96 (0.70- 1.30) 0.96 (0.53- 1.75) 0.96 (0.71- 1.28)
PON1 Q192R (rs662) Case 0.35 161 158 52 210
Control 0.36 159 167 52 219 0.833
OR (95% CI)* Reference 0.98 (0.72- 1.34) 1.06 (0.68- 1.65) 1.00 (0.75- 1.33)
NQO1 3' UTR (rs10517) Case 0.39 142 170 60 230
Control 0.35 154 181 44 225 0.162
OR (95% CI)* Reference 0.99 (0.73- 1.35) 1.44 (0.92- 2.26) 1.08 (0.81- 1.45)
NQO1 S1P (rs1800566) Case 0.46 109 181 78 259
Control 0.47 108 187 86 273 0.610
OR (95% CI)* Reference 1.00 (0.71- 1.39) 0.93 (0.62- 1.40) 0.98 (0.71- 1.34)
MnSOD V16A (rs4880) Case 0.22 241 107 31 138
Control 0.12 293 81 6 87 <0.001
OR (95% CI)* Reference 1.55 (1.11- 2.16) 6.05 (2.48- 14.74) 1.86 (1.35- 2.55)
MnSOD 3' UTR (rs5746136) Case 0.51 95 182 100 282
Control 0.46 118 178 85 263 0.058
OR (95% CI)* Reference 1.17 (0.83- 1.64) 1.34 (0.90- 1.99) 1.22 (0.89- 1.68)
SOD3 T58A (rs2536512) Case 0.25 235 96 44 140
Control 0.11 283 73 25 98 <0.001

















Table 3 Allelic and genotypic frequencies and risks for glioma in Chinese (Continued)
SOD3 3' UTR (rs2695232) Case 0.41 142 165 75 240
Control 0.41 134 172 70 242 0.922
OR (95% CI)* Reference 0.87 (0.63- 1.19) 0.97 (0.65- 1.45) 0.90 (0.67- 1.20)
NOS1 3' UTR (rs2682826) Case 0.25 209 104 23 127
Control 0.28 193 164 24 188 0.017
OR (95% CI)* Reference 0.57 (0.42- 0.79) 0.87 (0.47- 1.59) 0.61 (0.45- 0.82)
NOS1 Q902H (rs1047735) Case 0.46 123 165 90 255
Control 0.49 101 183 94 277 0.197
OR (95% CI)* Reference 0.80 (0.57- 1.11) 0.85 (0.57- 1.25) 0.81 (0.60- 1.11)
NOS2 L608S (rs2297518) Case 0.19 241 120 8 128
Control 0.17 255 113 9 122 0.584
OR (95% CI)* Reference 1.10 (0.80- 1.50) 0.92 (0.35- 2.42) 1.08 (0.80- 1.47)
NOS2 promoter (rs10459953) Case 0.40 140 178 64 242
Control 0.44 122 184 73 257 0.173
OR (95% CI)* Reference 0.88 (0.64- 1.21) 0.80 (0.53- 1.21) 0.86 (0.64- 1.16)
NOS3 D298E (rs1799983) Case 0.15 282 77 17 94
Control 0.12 278 84 15 99 0.856
OR (95% CI)* Reference 0.91 (0.64- 1.29) 1.12 (0.55- 2.29) 0.94 (0.68- 1.30)
*Multivariable adjustment by age, gender (male or female), smoking status (never, former or current), and pack-years.
Data in boldface represent P < 0.05.

















Table 4 Joint effects of unfavorable genotypes in case
patients and control subjects in Chinese
Risk group (no. unfavorable
genotypes)
Cases Controls OR (95% CI)*
Reference groupa (n = 0) 147 205 Reference
Low-risk reference group (n = 1) 96 83 1.51 (1.05- 2.17)
Medium-risk group (n = 2) 108 76 1.86 (1.30-2.67)
High-risk group b (n ≥3) 11 3 4.86 (1.33-17.71)
P for trend <0.001
*Adjusted for age, gender, smoking status, and pack-years.
aReference group: GPX1 promoter: CC, MnSOD V16A: TT, SOD3 T58A: GG, and
NOS1 3' UTR: CT+TT.
bBecause the subject number in group ‘4’ was sparse (one control and three
patients), the subjects with greater than three unfavourable genotypes were
combined as the high-risk group.
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tistically significant association between SOD2 rs4880
and the risk of glioma. Rajaraman P et al. [30] showed
an increased risk of acoustic neuroma with the SOD2
(Val16Ala) Ala variant, but no significant association
between the C genotype and the risk of glioma
was observed. The T-to-C nucleotide polymorphism
(rs4880), which converts a valine to an alanine in the
mitochondrial targeting sequence at position 16 of the
protein (Val16Ala), is considered one of the most
interesting polymorphisms in the SOD2 gene. The Val-
to-Ala transition alters the secondary structure of the
protein, resulting in more efficient transport of SOD2
into the mitochondrial matrix. Thus, the C allele can
increase the ability of SOD2 to neutralise superoxide
radicals compared to the T allele [45,46]. Diffuse inva-
sion into the surrounding brain is a characteristic fea-
ture of gliomas, essentially preventing surgical cure,
leading to recurrence and representing perhaps the lar-
gest obstacle to effective therapy. The invasive nature
of glioma cells into the brain parenchyma is intimately
linked to the degradation of the extracellular matrix.
Activated MMPs are a prerequisite for cancer cell in-
vasion and metastasis. Several lines of evidence have
suggested that the overexpression of SOD2 induces a
profound increase in the expression of MMP-1 [47-49].
Because the Ala mutant confers a 40% higher MnSOD
activity than the Val wild-type form, the increased levels
of SOD2 result in increased risk for more invasive gli-
oma activity by inducing MMPs. Our results are con-
sistent with this function of the SOD2 rs4880 in glioma
and warrant further investigation. A recent study has
indicated that SOD2 rs4880 might significantly modu-
late the prognosis of breast cancer patients [31], impli-
cating SOD2 rs4880 as a potential prognostic biomarker
in gliomas.
Our results also indicate a role for SOD3 rs2536512 in
the risk of glioma and demonstrated that the SOD3 A
genotype correlated with a significantly increased risk ofglioma occurrence in a Chinese population. SOD3 was
first detected in human plasma, lymph, ascites, and cere-
brospinal fluids [50]. This SNP (rs2536512) results in a
threonine-to-alanine conversion that replaces a polar
hydrophilic amino acid with an aliphatic hydrophobic
amino acid at position 58 of the SOD3 protein, eliminat-
ing a PKC delta phosphorylation motif [51]. Few studies
have been performed to examine the association be-
tween SOD3 rs699473 and glioma risk or to explore the
association between SOD3 rs2536512 and cerebral in-
farction in women [52]. Our study has demonstrated an
association between the human SOD3 gene and the risk
of glioma occurrence. Additionally, we observed statisti-
cally significant evidence that carriers of the SOD2 and
SOD3 variants exhibit increased glioma dose–response
relationships compared with homozygous wild-type sub-
jects (P-trend < 0.001). Confirmation of our findings in
alternate populations represents a high priority. The
SOD SNP-associated glioma risks observed in our study
suggest that the amino acid changes caused by these
SNPs might be physiologically significant in the develop-
ment of cancer.
GPX1 encodes the antioxidant glutathione peroxidase
isoform 1 and acts in conjunction with the tripeptide
glutathione (GSH), which is present in cells in high
(micromolar) concentrations [53]. Accumulating data
link altered or abnormal GPX1 expression with the aeti-
ology of cancer [54-56]. The additional identification of
GPX1 polymorphisms, concordant with several other
studies, suggests the involvement of GPX1 variants in
the aetiology of glioma [30,57]. In these previous studies,
the effect sizes occurred at an odds ratio of approxi-
mately 1.1; in our study, the rs1800668 SNP in GPX1
was associated with an almost 3.3-fold increased risk
when rare homozygotes were compared to common
homozygotes. Although the previous studies indicated
the same association that was observed in our results,
they lacked statistical significance and association. Thus,
it is likely that some associations that we have presented
here are chance findings. These data only provide evi-
dence that GPX1 rs1800668 contributes to glioma pre-
disposition. Further epidemiologic and functional studies
in a larger population are warranted to validate these
results.
Nitric oxide (NO), a pleiotropic messenger molecule,
is predominantly produced from the precursor L-
arginine by neuronal nitric oxide synthase (NOS1) in the
central nervous system [58,59]. The possible involve-
ment of NOS1 rs2682826 in vital functions has been
suggested by several studies. The rs2682826 SNP is
located in the 30-UTR of exon 29 of NOS1 gene. It has
been established that the 30-UTR plays a role in the sta-
bility and translational efficiency of the mRNA transcript
[60]. Additionally, the rs2682826 SNP is proximally
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30-UTR. Differences in protein translation might occur
depending on the presence of the SNP in the mRNA of
this gene [24]. Further functional analyses are required
to clarify these possibilities.
In this population sample, NOS1 rs2682826 might play
a protective role in the development of glioma under the
dominant model (adjusted OR = 0.61; 95% CI = 0.45–
0.82; P-trend = 0.017). Additional evidence substantiat-
ing the physiological relevance of the NOS1 rs2682826
polymorphisms was previously revealed by Ibarrola-
Villava et al. [24], who found that NOS1 rs2682826 is
associated with protective effects in malignant melan-
oma, accounting for a 40% reduction. If confirmed, the
evidence presented in this study here would facilitate the
identification of individuals who possess the heterozy-
gote or rare homozygote marker of NOS1 rs2682826.
These patients would particularly benefit from glioma
treatments.
However, the limitations of our study must be
addressed. First, these findings cannot be generalised to
other populations because our study was specifically
conducted using a Chinese population. Second, the
number of cases and controls included in this study was
relatively small; thus, further studies with larger sample-
sizes are needed.
In conclusion, we have demonstrated that the influ-
ence of these genetic variations in the oxidative response
has a potential regulatory effect on glioma tumourigen-
esis, and furthermore, we have identified a trend towards
an increasing glioma risk associated with an increasing
number of unfavourable genotypes that occur in a dose-
dependent manner. To our knowledge, this study pro-
vides the first epidemiological evidence that supports an
association between oxidative response-related genes
and glioma risk in a Chinese population. Further studies
are warranted to assess the observed effects using a
more comprehensive collection of SNPs in oxidative
response genes.Abbreviations
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